Earendil Labs and Genentech Announce Strategic Research Collaboration
1 report, 1 independent
Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Earendil Labs announced a research collaboration with Genentech to discover and develop multiple therapeutic bispecific antibody programs in oncology. Under the agreement, Earendil Labs will lead antibody discovery through the early clinical development stage for specific targets. Genentech will assume responsibility for the subsequent global clinical development and commercialization of these programs.
From manilatimes.net
Why it matters
The collaboration includes a $55 million upfront payment to Earendil Labs. The total potential value of the partnership, including future milestones, is reported to exceed $1.5 billion. Earendil Labs is also eligible to receive tiered royalties on net product sales.
From manilatimes.net
Who's involved
- Zhenping ZhuPresident & co-CEO of Earendil Labs
Keep exploring
The entities involved
-
Hoffmann-La Roche
Swiss healthcare company